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Effect of PAG1 on Src-family kinase trafficking in neuroblastoma cells 
Introduction 
 During embryonic development, a population of multipotent stem cells, known as the 
neural crest, migrates throughout the body and differentiates into a wide variety of tissues, 
including melanocytes, peripheral nervous tissue, and craniofacial cartilage. Extracellular cues, 
secreted by neighboring cells guide neural crest cells towards the correct cell fate, by binding 
cell-surface receptors to activate intracellular signaling cascades (1). 
 Neuroblastoma (NB) is a childhood cancer which develops when neural crest cells fail to 
differentiate and instead continue to proliferate. Neuroblastoma accounts for approximately 8% 
of pediatric cancers and nearly 15% of cancer mortalities in children. Because neural crest cells 
are multipotent and migratory, neuroblastoma is highly heterogenous and frequently metastatic at 
diagnosis, making it difficult to treat (2). Members of the receptor tyrosine kinase (RTK) family 
are known to regulate cell fate in neural crest and neuroblastoma cells and inappropriate 
signaling through RTK pathways are thought to contribute to neuroblastoma (3).  
 Among the downstream effectors of RTKs are Src-family kinases (SFKs), a family of 
non-receptor tyrosine kinases, which regulate migration, proliferation and differentiation. Upon 
activation of RTKs by external ligands, SFKs are recruited to the cytoplasmic tails of RTKs and 
phosphorylated, stabilizing them in the active form (4, 5). SFKs are further regulated by their 
location within the cell. Localization to lipid rafts can cluster SFKs with signaling partners. SFKs 
can also be endocytosed, where they can continue to signal from the surface of early and 
recycling endosomes, or be sequestered within the intraluminal vesicles (ILVs) of multivesicular 
endosomes (MVEs), carrier vesicles destined to fuse with late endosomes (6, 7, 8, 9). Once in 
ILVs, SFKs can be targeted to lysosomes and degraded, or released in exosomes. Exosomes are 
small extracellular vesicles (30-100nm in diameter) that are released when MVBs fuse with the 
plasma membrane. Exosomes are released by most cells in the body and carry out a number of 
functions. In cancer, they have been implicated in promoting metastasis and tumor-formation 
(10).  
 The scaffolding protein, PAG1, binds SFKs and controls their activity by regulating their 
movement within the cell and mediating their interaction with C-terminal SRC kinase (CSK), 
which down-regulates SFK activity by phosphorylating inhibitory residues (5). Previous studies 
have shown that after stimulation of SH-SY5Y neuroblastoma cells with RTK ligands, PAG1 is 
enriched in cell fractions containing the two SFKs, FYN and LYN (11). To investigate the role of 
PAG1 in SFK trafficking, a knock-down of PAG1 was attempted by transfecting SH-SY5Y cells 
with CRISPR/Cas9 plasmids targeting the PAG1 gene. Gene-sequencing of mutated SH-SY5Y 
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cells revealed a homozygous frameshift mutation, resulting in an early stop-codon, down-stream 
of the transmembrane region. Mass spectrometry and Western blotting analysis of mutants 
revealed expression of a truncated PAG1 protein, transcribed from a down-stream start codon. 
Since these cells express PAG1 which lacks the transmembrane domain, they are referred to as 
PAG1TM- cells.  
 Here, I show that PAG1TM- cells exhibit increased proliferation in comparison to wild-
type SH-SY5Y (WT) cells. Flow cytometry experiments have shown that PAG1TM- cells contain 
higher levels of active, phospho-SFKs (pSFKs). Based on this, we hypothesized that increased 
proliferation may be the result of hyper-active SFKs. To test this, I performed cell growth assays 
measuring the effects of SFK inhibition by PP2 treatment on proliferation in WT cells and 
PAG1TM- cells. Surprisingly, I found that PAG1TM- mutation actually decreased sensitivity to 
PP2. This led us to ask whether SFK activity is altered by differences in intracellular trafficking 
in PAG1TM- cells. Because previous data sets had indicated that FYN and LYN change location 
in response to RTK signaling (11), we have focused our experiments on these two SFKs. While 
fractionation experiments with PAG1TM- and WT cells did not indicate significant differences 
between location of FYN or LYN in endosomes, protease protection experiments suggested that 
pSFKs are targeted to MVBs in PAG1TM- cells. Since cargo in MVBs is primarily targeted either 
to the lysosome or released in exosomes, we hypothesized that PAG1TM- would alter the 
incorporation of SFKs into exosomes. To test this, I isolated exosomes from both WT and 
PAG1TM- cells to compare SFK content. 
Methods 
MTT assays: 
PAG1TM- and WT cells were seeded at 50,000 cells/well for 2-day experiments and 15,000 cells/
well for 3-day experiments in 96-well plates in 10%FBS RPMI 1640 medium. Day 0 wells were 
seeded from the same cell suspension as Day 2 or Day 3 wells, onto separate plates. At least six 
wells were seeded for each condition, and at least six blank wells were included on each plate to 
measure for background absorbance. One day after seeding, Day 0 measurements were taken. 
Seeding medium was replaced with 100μL 0.45mg/ml Thiazolyl Blue Tetrazolium Bromide 
(MTT) and left for four hours at 37°C to react with metabolizing cells. After 4 hours, 100μL of 
sodium dodecyl sulfate (SDS) in hydrochloric acid (pH=2) was added to each well to quench the 
reaction and dissolve the solid formazan product. After the formazan crystals had dissolved, 
absorbance at 570nm was measured by a VersaMax plate reader (Molecular Devices). For 
treatment wells, seeding medium was replaced with either PP2 (200nM, 500nM and 5μM) 
medium or vehicle control medium containing DMSO (ranging from 0.006% to 0.015% DMSO). 
Cells were left for either 2 or 3 days in treatment, after which MTT reactions were carried out, 
  !3
using the same procedure as for Day 0 wells. Previously conducted experiments showed that a 
linear relationship exists between cell number and absorbance at 570nm for absorbance values 
below 1.5 (data not shown). All absorbance readings for these experiments were less than 1.0 and 
were assumed to be directly proportional to the number of cells. The median blank absorbance 
was subtracted from all other absorbance readings from the same plate individually, and all 
subsequent calculations used background-corrected absorbance readings. 
Growth rate calculations: 
Growth rate refers to the number of doublings per day, as given by the formula:  
!  
where R is the calculated growth rate, !  and !  are the absorbance measurements before and 
after treatment, respectively, and t is the number of days for which cells were grown in PP2 or 
control medium. Growth rate was calculated for each Day 2 or Day3 well individually using the 
median !  value. A small number of wells generated negative growth rates, and were excluded 
from the data. If a set of replicate wells had more than two missing values, the whole set of data 
was also excluded. GRIs were calculated as described by Hafner et al., by the formula: 
!  
where R’ is the growth rate of cells under the test condition, and R is the control growth rate. In 
the case of PAG1-GRIs, R and R’ are the growth rates of WT and PAG1TM- cells respectively. For 
PP2-GRIs R is the growth rate of cells in vehicle-control medium, and R’ the growth rate of cells 
in PP2 medium. GRIs were calculated as the outer product, using each replicate R’ value in 
combination with each replicate R value. These calculations were carried out for five 
experiments individually. The resulting GRIs were pooled, and the second and third quartiles 
were used for analysis by plotting and in Welch’s t-tests. One-sample t-tests were also calculated 
for PP2-GRIs, to determine the statistical significance of growth rate inhibition (as indicated by 
deviation from 1). Calculations and graphs were done using the statistical programming 
language, R.  
Exosome isolation and analysis: 
WT and PAG1TM- cells were grown to between 90 and100% confluency, and media was replaced 
with serum-free DMEM, 24 hours prior to media collection. Conditioned media was centrifuged 
at 2,000 x g for 20 minutes, then 5,000 x g for 60 minutes to remove larger fragments. Exosomes 
were then pelleted by ultracentrifugation of the supernatant at 194,000 x g for 90 minutes. Pellets 
were then dissolved in 7M Urea buffer containing SDS and heated at 55º for 15 minutes. 
Samples were separated by SDS-PAGE. Western blots were stained with antibodies specific for 
FYN, LYN, pSRC and CD9 and imaged in a Fujifilm LAS-3000.  
R = [log2(At /A0)]/t
A0 At
A0
GRI = 2R′ /R − 1
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 Intensities of each SFK signal was divided by the intensity of CD9 from the same 
exosome sample to get an SFK/CD9 ratio for each cell type. The SFK/CD9 ratio for each cell 
type was then divided by the SFK/CD9 ratio in WT exosomes, as described by the formula: 
!  
Results 
PAG1TM- increases proliferation and decreases sensitivity to SFK inhibitor 
 To determine the effects of PAG1TM- mutation on proliferation, MTT assays were used to 
measure the growth rate of WT and PAG1TM- cells over 2 or 3 day growth periods. Effects on 
growth rate were interpreted by calculating the growth rate index (GRI), a normalized ratio 
which is robust against factors such as seeding density or culture volume, which are known to 
alter other growth rate metrics (12). Data were pooled from five replicate experiments. Due to 
high variability and the presence of outliers in the data, I restricted my analysis to the 
interquartile ranges of GRIs. PAG1-GRIs are the normalized ratio of PAG1TM- growth rates to 
WT growth rates. PAG1-GRIs were significantly greater than 1 under control conditions (Fig. 
1A, left) indicating that PAG1TM- increased proliferation. 
 Since PAG1TM- cells had been shown to contain higher levels of pSFKs, we wanted to 
determine whether SFK activity was responsible for the increased proliferation in PAG1TM- cells. 
To test this, I determined the growth rates of cells grown in the presence of PP2, an SFK 
inhibitor. PP2 is a tyrosine kinase inhibitor which is specific for SFKs at low concentrations (IC50 
for SFKs ranges from approximately 5nM to 100nM (13, 14)), but can have off-target effects on 
other tyrosine kinases including the EGF receptor (IC50 ~480nM) (14). PP2 was added to culture 
(
PAG1TM−SFK
PAG1TM−CD9
)/(
W TSFK
W TCD9
)
Figure 1: GRIs reveal increased 
growth rate in PAG1TM- cells and 
decreased sensitivity to PP2. Data was 
collected from five experiments. Boxplots 
show the interquartile range of PAG1-
GRIs (A) and PP2-GRIs (B) for each 
concentration of PP2. *P<0.05, 
**P<0.005, ***P<0.0005. Student’s t test 
was also calculated for pooled growth 
rates of WT vs. PAG1TM- cells. All P-
values were less than 0.05.  
BA
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media at concentrations of 0.2μM,  0.5μM and 
5μM. PP2-GRIs were calculated to compare 
proliferation during PP2 treatment to 
proliferation in control media. As expected 
PP2-GRIs were generally lower than 1 for both 
WT and PAG1TM- cells, indicating an inhibitory 
effect of PP2 on proliferation. Surprisingly, 
PP2-GRIs of PAG1TM- cells were much closer 
to 1 than PP2-GRIs of WT cells for all 
concentrations of PP2, indicating that PAG1TM- 
cells were less sensitive to SFK inhibition by 
PP2 than WT cells (Fig. 1B). At the lowest 
concentration of PP2, PP2-GRIs for PAG1TM- 
cells were not significantly different from 1 
(based on a Welch’s t-test), indicating growth 
rates of PAG1TM- cells were not affected by PP2 
at 0.2μM. WT cells however, did display 
decreased proliferation, with PP2-GRIs 
significantly lower than 1 (P=1.3x10-3). 
 PP2 treatment also increased PAG1-GRIs compared to untreated cells. Increasing 
concentration of PP2 exacerbated this difference, as PAG1-GRIs are significantly higher in cells 
treated with 5μM PP2 than in those treated with either 0.2μM or 0.5μM PP2 (P=1.7x10-3 and 
P=2.2x10-2, respectively). 
PAG1TM- decreases incorporation of LYN and pSFKs in exosomes 
 To determine whether PAG1TM- alters incorporation of SFKs into exosomes, I isolated 
exosomes from WT and PAG1TM- cells via ultracentrifugation. Protein contents of exosome 
samples were separated and analyzed on a Western blot. In addition to FYN, LYN and pSFKs, I 
probed samples for the exosomal marker, CD9, also known as Tetraspanin-29 (15) (Fig. 2D). 
Because CD9 is a general exosome marker, involved in clustering of cargo into ILVs, I assumed 
the intensity of CD9 to be proportional to the amount of exosomes in each sample, and the ratio 
of SFKs to CD9 to be proportional to the density of SFKs in exosomes. Because different 
antibodies have different binding characteristics, direct comparison between different probes is 
not meaningful. Instead, I focused on the differences in SFK densities between WT and PAG1TM- 
cells. Following this logic, each SFK signal was divided by the CD9 signal for each sample, to 
obtain SFK/CD9 ratios. To normalize between SFKs, each SFK/CD9 ratio was then divided by 
Figure 2: PAG1TM- decreases LYN and pSFK in 
exosomes. Exosomes were isolated from WT and 
PAG1TM- cells and probed for FYN, LYN, pSFK and 
CD9. To determine the relative amount of SFKs 
expressed in exosomes, the FYN(A), LYN (B) and 
pSFK (C) signal was divided by the CD9 signal for 
each sample. The resulting SFK to CD9 ratio was 
then divided by the SFK to CD9 ratio for WT cells to 
get a percentage of the WT ratio. (D) shows Western 
blot images.
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the corresponding WT SFK/CD9 ratio, and shown as a percentage (Fig. 2A-C). I found that 
PAG1TM- decreased the density of LYN in exosomes (Fig. 2B) but had a negligible effect on 
FYN (Fig. 2A). Surprisingly, PAG1TM- exosomes also contained lower levels of pSFKs than WT 
exosomes (Fig. 2C).  
Discussion  
 SFKs are known to be important in controlling cell fate, yet the precise roles of different 
SFKs are not well-characterized. SFKs act within dense and overlapping signaling networks, in 
which phosphorylation, as well as intracellular location regulate their activity. Localization of 
SFKs to lipid rafts is known to increase SFK activities by bringing them into proximity with 
signaling partners (5). Signaling kinases which are targeted to endosomes, but remain on the 
cytosolic surface of early endosomes, can continue to transduce signals by interacting with 
cytosolic proteins (7). On the other hand, movement of signaling proteins into MVEs can 
sequester them from target proteins, and thereby down-regulate their activity (9). From MVEs, 
cargo is typically moved into lysosomes to be degraded, or secreted in exosomes (10). PAG1 
binds SFKs to facilitate their interaction with regulatory proteins (5). We believe that PAG1 also 
directs their movement within signaling compartments.  
 Here, I have shown that cells expressing PAG1TM- proliferate faster than WT cells (Fig. 
1A). Because previous experiments have shown that PAG1TM- cells contain higher levels of 
pSFKs (unpublished data), we hypothesized that hyper-activation of SFKs  in PAG1TM- cells led 
to increased proliferation. However, proliferation assays with the SFK-inhibitor PP2, showed 
that PAG1TM- cells were less sensitive to PP2 than WT cells (Fig. 1). This may have to do with 
the particular SFKs which are hyper-activated in PAG1TM- cells. While SRC is known to drive 
proliferation (11), other SFKs may have suppressive effects on proliferation. FYN and LYN are 
both driven out of lipid rafts and into lysosomes in response to stimulation of pro-pluripotency 
RTKs, suggesting that they may promote a more differentiated, and less proliferative phenotype 
for neuroblastoma cells (11).  
 It is also important to note that increased phosphorylation of SFKs does not necessarily 
imply increased signaling ability. Decreased sensitivity to PP2 in PAG1TM- cells, could also be 
related to the location of SFKs within PAG1TM- cells. Protease protection experiments have 
indicated that FYN, LYN and pSFKs are all abundantly trafficked to MVEs in PAG1TM- cells, 
whereas only LYN is trafficked to MVEs in WT cells (Lauren Foltz, unpublished observations). 
Previous studies have shown that SH-SY5Ys release exosomes containing LYN and, to a lesser 
extent, FYN (9, 16). I have shown that exosomes released by PAG1TM--expressing SH-SY5Y 
cells contained lower levels of LYN and pSFKs (Fig. 2A,C). The density of FYN in PAG1TM- 
exosomes was similar to that in WT exosomes (Fig. 2B). Since more FYN is targeted to MVEs 
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in PAG1TM- cells than in WT cells, this would still imply that a decreased fraction of the total 
FYN in PAG1TM- MVEs is incorporated into exosomes. This may suggest that SFKs in the 
MVEs of PAG1TM- cells are mainly targeted to lysosomes for degradation, rather than being 
released in exosomes, although this would need to be tested directly. 
 How MVEs are targeted to exosomes, as opposed to lysosomes is not well understood. 
PAG1 may be required to escort SFKs, or simply to direct SFKs towards MVEs which are 
destined to release exosomes. Further studies into how cargo in MVEs is targeted to the correct 
destination may help elucidate the role of PAG1 and SFKs in regulating cell fate of 
neuroblastoma cells.  
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